The Filings Report

Neurocrine Biosciences Inc

NBIXNasdaqCIK 914475Healthcare / Biotechnologyfiscal year ends December66 quarters since 2010

Revenue, Q3 FY2026
$1.1B
+41.2% on Q3 FY2025
Net income
$207M
−1.4% on Q3 FY2025
Free cash flow
$384M
+79.0% on Q3 FY2025
Diluted EPS
$1.96
−3.9% on Q3 FY2025
Revenue, TTM
$3.7B
trailing four quarters
Net margin, TTM
19.0%
net income $703M
Free cash flow, TTM
$1.0B
$1.1B less $26M capex
Cash and equivalents
$642M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+1.5%
101M shares, Sep 30, 2026
Buybacks, TTM
$158M
1.1% of market value
Dividends, TTM
—
no yield
Market value
$14.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 2, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Neurocrine Biosciences Inc reported revenue of $1.1B, +41.2% on Q3 FY2025, and net income of $207M (−1.4%). Operating margin was 29.5%. Free cash flow, operating cash flow less capital expenditures, was $384M ($395M less $12M). Diluted earnings per share were $1.96.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 2, 2026.

Revenue and net incomeRevenueNet income
−$500M$0$500M$1.0B$1.5BQ4'22, Revenue: $412MQ4'22, Net income: $89MQ4'22Q1'23, Revenue: $420MQ1'23, Net income: −$77MQ1'23Q2'23, Revenue: $453MQ2'23, Net income: $96MQ2'23Q3'23, Revenue: $499MQ3'23, Net income: $83MQ3'23Q4'23, Revenue: $515MQ4'23, Net income: $148MQ4'23Q1'24, Revenue: $515MQ1'24, Net income: $43MQ1'24Q2'24, Revenue: $590MQ2'24, Net income: $65MQ2'24Q3'24, Revenue: $622MQ3'24, Net income: $130MQ3'24Q4'24, Revenue: $628MQ4'24, Net income: $103MQ4'24Q1'25, Revenue: $573MQ1'25, Net income: $8MQ1'25Q2'25, Revenue: $688MQ2'25, Net income: $108MQ2'25Q3'25, Revenue: $795MQ3'25, Net income: $210MQ3'25Q4'25, Revenue: $806MQ4'25, Net income: $154MQ4'25Q1'26, Revenue: $815MQ1'26, Net income: $198MQ1'26Q2'26, Revenue: $959MQ2'26, Net income: $144MQ2'26Q3'26, Revenue: $1.1BQ3'26, Net income: $207MQ3'26−$500M$0$500M$1.0B$1.5BQ4'22, Revenue: $412MQ4'22, Net income: $89MQ1'23, Revenue: $420MQ1'23, Net income: −$77MQ1'23Q2'23, Revenue: $453MQ2'23, Net income: $96MQ3'23, Revenue: $499MQ3'23, Net income: $83MQ3'23Q4'23, Revenue: $515MQ4'23, Net income: $148MQ1'24, Revenue: $515MQ1'24, Net income: $43MQ1'24Q2'24, Revenue: $590MQ2'24, Net income: $65MQ3'24, Revenue: $622MQ3'24, Net income: $130MQ3'24Q4'24, Revenue: $628MQ4'24, Net income: $103MQ1'25, Revenue: $573MQ1'25, Net income: $8MQ1'25Q2'25, Revenue: $688MQ2'25, Net income: $108MQ3'25, Revenue: $795MQ3'25, Net income: $210MQ3'25Q4'25, Revenue: $806MQ4'25, Net income: $154MQ1'26, Revenue: $815MQ1'26, Net income: $198MQ1'26Q2'26, Revenue: $959MQ2'26, Net income: $144MQ3'26, Revenue: $1.1BQ3'26, Net income: $207MQ3'26

Net income losses drawn in red.

Free cash flow
−$200M$0$200M$400MQ4'22, Free cash flow: $141MQ4'22Q1'23, Free cash flow: −$134MQ1'23Q2'23, Free cash flow: $173MQ2'23Q3'23, Free cash flow: $204MQ3'23Q4'23, Free cash flow: $118MQ4'23Q1'24, Free cash flow: $119MQ1'24Q2'24, Free cash flow: $53MQ2'24Q3'24, Free cash flow: $150MQ3'24Q4'24, Free cash flow: $235MQ4'24Q1'25, Free cash flow: $54MQ1'25Q2'25, Free cash flow: $90MQ2'25Q3'25, Free cash flow: $214MQ3'25Q4'25, Free cash flow: $391MQ4'25Q1'26, Free cash flow: $137MQ1'26Q2'26, Free cash flow: $129MQ2'26Q3'26, Free cash flow: $384MQ3'26−$200M$0$200M$400MQ4'22, Free cash flow: $141MQ1'23, Free cash flow: −$134MQ1'23Q2'23, Free cash flow: $173MQ3'23, Free cash flow: $204MQ3'23Q4'23, Free cash flow: $118MQ1'24, Free cash flow: $119MQ1'24Q2'24, Free cash flow: $53MQ3'24, Free cash flow: $150MQ3'24Q4'24, Free cash flow: $235MQ1'25, Free cash flow: $54MQ1'25Q2'25, Free cash flow: $90MQ3'25, Free cash flow: $214MQ3'25Q4'25, Free cash flow: $391MQ1'26, Free cash flow: $137MQ1'26Q2'26, Free cash flow: $129MQ3'26, Free cash flow: $384MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600M$800MQ4'22, Cash and equivalents: $263MQ4'22Q1'23, Cash and equivalents: $104MQ1'23Q2'23, Cash and equivalents: $160MQ2'23Q3'23, Cash and equivalents: $294MQ3'23Q4'23, Cash and equivalents: $251MQ4'23Q1'24, Cash and equivalents: $396MQ1'24Q2'24, Cash and equivalents: $140MQ2'24Q3'24, Cash and equivalents: $349MQ3'24Q4'24, Cash and equivalents: $233MQ4'24Q1'25, Cash and equivalents: $194MQ1'25Q2'25, Cash and equivalents: $264MQ2'25Q3'25, Cash and equivalents: $340MQ3'25Q4'25, Cash and equivalents: $713MQ4'25Q1'26, Cash and equivalents: $267MQ1'26Q2'26, Cash and equivalents: $332MQ2'26Q3'26, Cash and equivalents: $642MQ3'26$0$200M$400M$600M$800MQ4'22, Cash and equivalents: $263MQ1'23, Cash and equivalents: $104MQ1'23Q2'23, Cash and equivalents: $160MQ3'23, Cash and equivalents: $294MQ3'23Q4'23, Cash and equivalents: $251MQ1'24, Cash and equivalents: $396MQ1'24Q2'24, Cash and equivalents: $140MQ3'24, Cash and equivalents: $349MQ3'24Q4'24, Cash and equivalents: $233MQ1'25, Cash and equivalents: $194MQ1'25Q2'25, Cash and equivalents: $264MQ3'25, Cash and equivalents: $340MQ3'25Q4'25, Cash and equivalents: $713MQ1'26, Cash and equivalents: $267MQ1'26Q2'26, Cash and equivalents: $332MQ3'26, Cash and equivalents: $642MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Neurocrine Biosciences Inc income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 10, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,123959815806795688573628+41.2%
Cost of revenue——1418141199—
Gross profit—————————
Research and development—————————
Selling, general and administrative366440319302292286277288+25.6%
Operating income33115219321123914624142+38.6%
Other income (expense)(48)1153295314(9)21−190.2%
Pretax income28416224723929216015163−2.8%
Income tax771849868252760−6.2%
Net income2071441981542101088103−1.4%
Diluted EPS ($)1.961.391.91—2.041.060.08—−3.9%
Diluted shares (millions)105104103—103101103——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Neurocrine Biosciences Inc balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 10, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents642332267713340264194233+88.6%
Short-term investments96571,050767775712749843−87.6%
Total current assets2,0081,6382,4362,5232,1581,7491,6381,725−7.0%
Total assets5,6275,3594,9064,6324,2663,8903,6883,719+31.9%
Total current liabilities985875832743638546523508+54.3%
Long-term debt—————————
Total liabilities1,7491,6661,4991,3781,2621,1961,1521,129+38.6%
Stockholders’ equity3,8793,6943,4073,2533,0042,6942,5362,590+29.1%
Shares outstanding (millions)1011021011001009999100—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 2, 2026.

Neurocrine Biosciences Inc cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 2, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 10, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow39513614638822810265243+73.7%
Capital expenditures1289(2)1313117−12.1%
Free cash flow (CFO − capex)3841291373912149054235+79.0%
Depreciation and amortization—————————
Share repurchases9212540018150300—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 11, 2026.

Income statement

Neurocrine Biosciences Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 10, 2025FY2023ended Dec 31, 2023filed Feb 9, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 5, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 8, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 9, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Feb 8, 2013FY2011ended Dec 31, 2011filed Feb 9, 2012FY2010ended Dec 31, 2010filed Jul 29, 2011FY2009ended Dec 31, 2009filed Jul 29, 2011
Revenue2,8612,3551,8871,4891,1341,0467884511621520035377343
Cost of revenue523440231410—510———————
Gross profit—————————————————
Research and development———————1611229481463937313134
Selling, general and administrative1,1561,0078887535834333542491706832181313121314
Operating income6195712512491031637237(131)(147)(94)(64)(50)134(14)(54)
Other income (expense)86(84)81(35)(1)(56)(26)(15)(11)65444463
Pretax income7054863322141011074722(143)(141)———————
Income tax227145825912(301)1010000000——
Net income479341250155904073721(143)(141)(89)(61)(46)538(8)(51)
Diluted EPS ($)4.673.292.471.560.924.160.390.22(1.62)(1.63)(1.05)(0.81)(0.69)0.080.67(0.15)(1.30)
Diluted shares (millions)1031041019998989695888784756767565339

Balance sheet

Neurocrine Biosciences Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 10, 2025FY2023ended Dec 31, 2023filed Feb 9, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 5, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 8, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 9, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Feb 8, 2013FY2011ended Dec 31, 2011filed Feb 9, 2012FY2010ended Dec 31, 2010filed Jul 29, 2011FY2009ended Dec 31, 2009filed Jul 29, 2011
Cash and equivalents7132332512633411871121422558374314564505437
Short-term investments767843781726371614558509261——1631011097973—
Total current assets2,5231,7251,6071,4549731,016831738555310384198148189132133—
Total assets4,6323,7193,2512,3692,0731,7351,306993818365475243155196138144—
Total current liabilities743508655538246187565885430261612164753—
Long-term debt—————————————————
Total liabilities1,3781,1291,019661699609669512445505034344278125—
Stockholders’ equity3,2532,5902,2321,7081,3741,12663748137231542420912015460194
Shares outstanding (millions)100100100979594929189878677686766——

Cash flow statement

Neurocrine Biosciences Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 11, 2026FY2024ended Dec 31, 2024filed Feb 10, 2025FY2023ended Dec 31, 2023filed Feb 9, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 5, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 8, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 9, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Feb 8, 2013FY2011ended Dec 31, 2011filed Feb 9, 2012FY2010ended Dec 31, 2010filed Jul 29, 2011FY2009ended Dec 31, 2009filed Jul 29, 2011
Operating cash flow783595390339257229147101(94)(106)——(30)(35)(1)50(53)
Capital expenditures3438281723111525742211100
Free cash flow (CFO − capex)74955736232323321813277(101)(110)——(30)(36)(1)50(53)
Depreciation and amortization———————4211111113
Share repurchases16830000—————————————
Dividends paid—————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$3M
15 sales by 4 insiders; officers and directors $3M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$80M
52 sales by 15 insiders; officers and directors $80M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 3, 2026Morrow George JDirectoroption exercise7,200$53.64$386K17,586Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-1100$158.18$16K17,486Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-1100$162.05$16K17,386Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-1600$163.71$98K16,786Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-11,226$164.74$202K15,560Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-1908$165.71$150K14,652Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-11,466$166.77$244K13,186Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-11,500$167.72$252K11,686Nov 3, 2026
Nov 3, 2026Morrow George JDirectoropen-market sale10b5-11,300$168.53$219K10,386Nov 3, 2026
Nov 2, 2026Morrow George JDirectoroption exercise7,500$53.64$402K17,886Nov 3, 2026
Nov 2, 2026Morrow George JDirectoropen-market sale10b5-11,900$144.98$275K15,986Nov 3, 2026
Nov 2, 2026Morrow George JDirectoropen-market sale10b5-14,300$145.86$627K11,686Nov 3, 2026
Nov 2, 2026Morrow George JDirectoropen-market sale10b5-11,300$146.76$191K10,386Nov 3, 2026
Nov 1, 2026Gano KyleChief Executive Officer, Directoroption exercise614$0.00—155,342Nov 3, 2026
Nov 1, 2026Gano KyleChief Executive Officer, Directortax withholding332$146.10$49K155,010Nov 3, 2026
Oct 30, 2026Morrow George JDirectoroption exercise300$53.64$16K10,686Nov 3, 2026
Oct 30, 2026Morrow George JDirectoropen-market sale10b5-1300$149.00$45K10,386Nov 3, 2026
Sep 14, 2026Boyer David W.Chief Corp. Affairs Officeropen-market sale10b5-1826$157.45$130K8,722Sep 15, 2026
Sep 14, 2026Abernethy MattChief Financial Officeropen-market sale10b5-12,311$157.20$363K42,808Sep 15, 2026
Sep 11, 2026Onyia JudeChief Scientific Officeraward3,587$0.00—24,583Sep 15, 2026
Sep 11, 2026Onyia JudeChief Scientific Officertax withholding1,936$156.22$302K22,647Sep 15, 2026
Sep 11, 2026Lippoldt DarinChief Legal Officeraward4,483$0.00—59,212Sep 15, 2026
Sep 11, 2026Lippoldt DarinChief Legal Officertax withholding2,419$156.22$378K56,793Sep 15, 2026
Sep 11, 2026Keswani Sanjay ChandruChief Medical Officeraward3,914$0.00—5,393Sep 15, 2026
Sep 11, 2026Keswani Sanjay ChandruChief Medical Officertax withholding2,112$156.22$330K3,281Sep 15, 2026

Full insider history for Neurocrine Biosciences Inc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
NEUROCRINE BIOSCIENCES, INC., CIK 914475 on EDGAR
Extract generated
November 4, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2021
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/NBIX.json